Hudson Bay Capital Management
AERI

Hudson Bay Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Hudson Bay Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-71,210
Closed -$3.46M – 570
2017
Q3 		$3.46M Buy
71,210
+31,210
+78% +$1.7M 0.09% 185
2017
Q2 		$2.1M Buy
+40,000
New +$1.86M 0.04% 330

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hudson Bay Capital Management's AERI Position: Q4 2017 in Review

Hudson Bay Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2017, closing a stake of 71,210 shares — an estimated $3.46M sold.

Hudson Bay Capital Management first reported a position in AERI in Q2 2017 and held it in 2 quarters. The position peaked at $3.46M in Q3 2017. 179 funds tracked by Wall St. Rank hold AERI as of Q4 2017.

  • Hudson Bay Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Hudson Bay Capital Management sold 71,210 Aerie Pharmaceuticals shares in Q4 2017, an estimated $3.46M.
  • Hudson Bay Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Hudson Bay Capital Management's Aerie Pharmaceuticals position peaked at $3.46M in Q3 2017.
  • 179 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2017.

Based on Hudson Bay Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.